Anti-Asthmatics And COPD Drugs Market Size, Share And Forecast To 2033

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Anti-Asthmatics And COPD Drugs Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $104.1 billion In 2028 At A CAGR Of 6.3% :

The anti-asthmatics and copd drugs market size has grown strongly in recent years. It will grow from $76.16 billion in 2023 to $81.41 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to include increased prevalence of respiratory diseases, increased incidence of tobacco smoking, global warming, geriatric population, emerging markets, new methods for drug discovery, rise in healthcare expenditure.

The anti-asthmatics and copd drugs market size is expected to see strong growth in the next few years. It will grow to $104.1 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increased popularity of e-cigarettes/ vaping, rising obesity levels, technology, large pool of undiagnosed population, use of anti-asthmatics and copd drugs to treat covid-19 patients, increasing consumption of fats . Major trends in the forecast period include developing probiotic drugs for asthma to offer a full range of available treatments, developing anti-il-5 drugs to expand their business portfolio, launching new innovative products to focus on establishing their market position and sustain their position among intense competition in the market, invest more in developing bioelectric medicines to improve asthma care, focus on increasing the number of collaborations to expand their business portfolio, explore opportunities in personalized medicine to counter the intense competition and provide customized treatment to individuals, invest in aerosol respiratory drugs for better efficacy, investing in biomarkers to produce more effective drugs in a smaller time frame, focus efforts on investing in generic drugs to counter the intense competition, developing combination drugs to offer better result, developing biologics to capitalize on the growing demand for biologics..

Request A Sample Of This Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=3802&type=smp

Anti-Asthmatics And COPD Drugs Market Major Segments
The anti-asthmatics and copd drugs market covered in this report is segmented -
1) By Drug Class: Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, Combination Drugs
2) By Distribution Channel: Hospital Pharmacies, General Pharmacies, Online Retailers
3) By End User: Asthma Patients, COPD Patients
4) By Therapy: Preventive, Curative
5) By Route Of Administration: Oral, Inhaled, Intravenous, Subcutaneous
6) By Age Group: Below 5, 5-14, 15-60, Above 60

Key Driver - Modifiable Risk Factors Propel Anti-Asthmatics And Copd Drug Market

Modifiable risk factors including smoking, lack of physical exercise, and unhealthy eating habits drive the Asthma and COPD drugs market. Even though there is a decreasing trend in smoking prevalence globally, developing countries such as China, India, Indonesia, and Nigeria among others have increasing smoking prevalence. For instance, the number of tobacco smokers is set to increase by 24 million in Indonesia and by 7 million in Nigeria by 2025, and more than 40% of global cigarette consumption is concentrated in China. Consumption of fats including saturated fatty acids which is a risk factor for Asthma and COPD is more in high-income countries including the USA and Europe. According to WHO, in developed countries, more than 35% of total energy requirement is derived from fats when compared to in low-income countries, and less than 25% in lower-middle-income countries.

Customise This Report As Per Your Requirements -
https://www.thebusinessresearchcompany.com/Customise?id=3802&type=smp

Prominent Trend - Innovative Fdc Drug Indacaterol Plus Mometasone Strengthens Leading Companies In The Anti-Asthmatics And Copd Drugs Market

Major companies operating in the anti-asthmatics and COPD drugs market are innovating new products such as dose combination (FDC) drug, Indacaterol plus Mometasone to increase their profitability in the market. Indacaterol plus Mometasone, delivered via the Breezhaler device, is a once-daily fixed-dose combination (FDC) medication designed for the ongoing management of asthma in patients. For instance, in June 2022 Glenmark Pharmaceuticals, a US-based pharmaceutical company launched a novel-fixed dose combination (FDC) drug, Indacaterol plus Mometasone, for patients suffering from uncontrollable asthma in India. The medication, marketed as Indamet, is offered in three variations, all containing a consistent dose of 150 mcg of Indacaterol and variable doses of Mometasone, which come in 80 mcg, 160 mcg, and 320 mcg strengths.

Anti-Asthmatics And COPD Drugs Market Players
Major companies operating in the anti-asthmatics and copd drugs market report are GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Sumitomo Dainippon Pharma Co. Ltd., China National Pharmaceutical Group Co. Ltd. (Sinopharm), Shanghai Acebright Pharmaceuticals Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd, Hanmi Pharmaceutical, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd, GSK, Shanghai Anovent Pharma, China Meheco Group Co. Ltd., Lupin Limited, ASGEN Pharmaceutical Co. Ltd, Abbott Laboratories, Pfizer, Vectura Group, Bristol Myers Squibb, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Bayer, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Cipla Medpro South Africa (Pty) Limited, Aspen Nigeria

View The Full Report Here -
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the anti-asthmatics and COPD drugs market in 2023. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and copd drugs market during the forecast period. The regions covered in the anti-asthmatics and copd drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Anti-Asthmatics And COPD Drugs Market Report Structure
3. Anti-Asthmatics And COPD Drugs Market Trends And Strategies
4. Anti-Asthmatics And COPD Drugs Market - Macro Economic Scenario
5. Anti-Asthmatics And COPD Drugs Market Size And Growth
…..
27. Anti-Asthmatics And COPD Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.